Scoparic Acid C

Scoparic Acid C

SCHEMBL16610413

C=C(C=O)CC[C@@H]1C(=C)C[C@@H](OC(=O)c2ccccc2)C2[C@](C)(C(=O)O)CCC[C@@]21C

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
TP53 P04637 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPK1 P28482 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
TRPC6 Q9Y210 4/20 0.40
TRPC3 Q13507 1/20 0.39
PTPN1 P18031 1/20 0.35
TTL Q8NG68 2/20 0.33
POLB P06746 1/20 0.33
PRKCA P17252 1/20 0.32
ALOX15 P16050 1/20 0.32
GAA P10253 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Scoparic Acid C SCHEMBL30621454 1.00 MAPT (0.41) MAPTTP53CYP3A4MAPK1MEN1
Scoparic Acid B SCHEMBL14554122 0.89 MAPT (0.43) MAPTTP53CYP3A4MAPK1MEN1
Scoparic Acid B SCHEMBL30621452 0.89 MAPT (0.43) MAPTTP53CYP3A4MAPK1MEN1
SCHEMBL14552895 0.89 TP53 (0.40) MAPTTP53CYP3A4MAPK1MEN1
SCHEMBL16606703 0.89 TP53 (0.40) MAPTTP53CYP3A4MAPK1MEN1
Scoparic Acid A SCHEMBL31051329 0.86 MAPT (0.42) MAPTTP53CYP3A4MAPK1MEN1
Scoparic Acid A SCHEMBL30621453 0.86 MAPT (0.42) MAPTTP53CYP3A4MAPK1MEN1
Scoparic Acid A SCHEMBL16610421 0.86 MAPT (0.42) MAPTTP53CYP3A4MAPK1MEN1
SCHEMBL16606704 0.80 TP53 (0.43) MAPTTP53CYP3A4MAPK1MEN1
SCHEMBL14552920 0.80 TP53 (0.43) MAPTTP53CYP3A4MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150093371-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE Humanitas Technology, LLC (US) 2015-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150093371-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE DDX5, MAVS, EIF2AK2 MAPT 4177/4885TP53 2391/4885CYP3A4 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.